• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.

作者信息

Crusz S M, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek P W, Shamash J, Rashid S

机构信息

Department of Medical Oncology, Barts Health NHS Trust, Basement Level, KGV Building, London, EC1A 7BE, UK.

Department of Neurology, Barts Health NHS Trust, 4th Floor Front Block, Whitechapel, London, EH1 1BB, UK.

出版信息

Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20.

DOI:10.1016/j.ejca.2018.07.125
PMID:30138772
Abstract
摘要

相似文献

1
Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.利妥昔单抗治疗帕博利珠单抗诱导的重症肌无力
Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20.
2
Refractory myasthenia gravis exacerbation triggered By pembrolizumab.派姆单抗引发的难治性重症肌无力加重
Muscle Nerve. 2018 Apr;57(4):E120-E121. doi: 10.1002/mus.26021. Epub 2017 Dec 7.
3
Pembrolizumab-associated ocular myasthenia gravis.帕博利珠单抗相关的眼肌型重症肌无力
Clin Exp Ophthalmol. 2019 Aug;47(6):796-798. doi: 10.1111/ceo.13499. Epub 2019 Apr 1.
4
Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.在一名接受抗程序性死亡1抗体治疗的黑色素瘤患者中，出现针对横纹肌和乙酰胆碱受体的抗体，并伴有重症肌无力合并肌炎和心肌炎。
Eur J Cancer. 2019 Jan;106:193-195. doi: 10.1016/j.ejca.2018.10.025. Epub 2018 Dec 5.
5
Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.两例在对派姆单抗治疗有反应的黑色素瘤患者中出现的与使用派姆单抗相关的临床重症肌无力病例。
Melanoma Res. 2017 Apr;27(2):152-154. doi: 10.1097/CMR.0000000000000310.
6
Pembrolizumab-Induced Alopecia Areata.帕博利珠单抗诱发的斑秃。
Skinmed. 2019 May 29;17(2):142-143. eCollection 2019.
7
Acute localised exanthematous pustulosis secondary to pembrolizumab.帕博利珠单抗继发的急性局限性发疹性脓疱病
Australas J Dermatol. 2017 Nov;58(4):322-323. doi: 10.1111/ajd.12594. Epub 2017 Jul 10.
8
Myasthenia gravis exacerbation associated with pembrolizumab.与帕博利珠单抗相关的重症肌无力加重。
Muscle Nerve. 2016 Sep;54(3):506-7. doi: 10.1002/mus.25055. Epub 2016 Mar 12.
9
Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.帕博利珠单抗诱导的伴抗肌联蛋白抗体和坏死性肌病的眼肌型重症肌无力
Intern Med. 2019 Jun 1;58(11):1635-1638. doi: 10.2169/internalmedicine.1956-18. Epub 2019 Feb 1.
10
Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.帕博利珠单抗治疗转移性黑色素瘤相关的迟发性皮肤毒性。
Eur J Dermatol. 2019 Jun 1;29(3):349-351. doi: 10.1684/ejd.2019.3592.

引用本文的文献

1
Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report.依库珠单抗作为帕博利珠单抗诱导的重症肌无力即将发生危机状态的快速起效抢救治疗：一例报告
Ther Adv Neurol Disord. 2025 Apr 22;18:17562864251333518. doi: 10.1177/17562864251333518. eCollection 2025.
2
Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma.帕博利珠单抗诱导的重症肌无力合并心肌炎伴转移性肾细胞癌
Cureus. 2024 Aug 31;16(8):e68318. doi: 10.7759/cureus.68318. eCollection 2024 Aug.
3
Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
免疫检查点抑制剂诱导的肌炎/重症肌无力重叠综合征
Cureus. 2023 Nov 18;15(11):e49007. doi: 10.7759/cureus.49007. eCollection 2023 Nov.
4
Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.探索免疫检查点抑制剂在重症肌无力和兰伯特-伊顿肌无力综合征病因学中的作用：一项系统评价。
Front Neurol. 2023 Jan 9;13:1004810. doi: 10.3389/fneur.2022.1004810. eCollection 2022.
5
Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors.帕博利珠单抗诱发的重症肌无力和肌炎：程序性死亡蛋白1抑制剂神经毒性的文献综述
J Med Cases. 2022 Nov;13(11):530-535. doi: 10.14740/jmc4008. Epub 2022 Nov 27.
6
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.免疫检查点抑制剂相关不良事件的整体处理方法
Front Immunol. 2022 Mar 30;13:804597. doi: 10.3389/fimmu.2022.804597. eCollection 2022.
7
Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.免疫检查点抑制剂再挑战的神经毒性和安全性：神经肿瘤学实践中的一个日益严重的问题。
Neurol Sci. 2022 Apr;43(4):2339-2361. doi: 10.1007/s10072-022-05920-4. Epub 2022 Feb 17.
8
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis.利妥昔单抗治疗免疫检查点抑制剂相关重症肌无力
Cureus. 2021 Jul 12;13(7):e16337. doi: 10.7759/cureus.16337. eCollection 2021 Jul.
9
Adverse events induced by immune checkpoint inhibitors.免疫检查点抑制剂引起的不良反应。
Curr Opin Immunol. 2021 Apr;69:29-38. doi: 10.1016/j.coi.2021.02.002. Epub 2021 Feb 25.
10
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂的神经眼科并发症：一项系统综述
Eye Brain. 2020 Nov 3;12:139-167. doi: 10.2147/EB.S277760. eCollection 2020.